CNS Drugs

, Volume 19, Issue 1, pp 13–25 | Cite as

Novel Approaches to the Treatment of Cocaine Addiction

  • Mehmet SofuogluEmail author
  • Thomas R. Kosten
Leading Article


Cocaine addiction continues to be an important public health problem with over 1.7 million users in the US alone. Although there are no approved pharmacotherapies for cocaine addiction, a number of medications have been tested with some promising results. In this review, we summarise some of the emerging targets for cocaine pharmacotherapy including dopaminergic and GABA medications, adrenoceptor antagonists, vasodilators and immunotherapies. The brain dopamine system plays a significant role in mediating the rewarding effects of cocaine. Among dopaminergic agents tested for cocaine pharmacotherapy, disulfiram has decreased cocaine use in a number of studies. Amantadine, another medication with dopaminergic effects, may also be effective in cocaine users with high withdrawal severity. GABA is the main inhibitory neurotransmitter in the brain, and accumulating evidence suggests that the GABA system modulates the dopaminergic system and cocaine effects. Two anticonvulsant medications with GABAergic effects, tiagabine and topiramate, have yielded positive findings in clinical trials. Baclofen, a GABAb receptor agonist, is also promising, especially in those with more severe cocaine use. Some of the physiological and behavioural effects of cocaine are mediated by activation of the adrenergic system. In cocaine users, propranolol, a β-adrenoceptor antagonist, had promising effects in individuals with more severe cocaine withdrawal symptoms. Cerebral vasodilators are another potential target for cocaine pharmacotherapy. Cocaine users have reduced cerebral blood flow and cortical perfusion deficits. Treatment with the vasodilators amiloride or isradipine has reduced perfusion abnormalities found in cocaineusers. The functional significance of these improvements needs to be further investigated. All these proposed pharmacotherapies for cocaine addiction act on neural pathways. In contrast, immunotherapies for cocaine addiction are based on the blockade of cocaine effects peripherally, and as a result, prevent or at least slow the entry of cocaine into the brain. A cocaine vaccine is another promising treatment for cocaine addiction. The efficacy of this vaccine for relapse prevention is under investigation. Many initial promising findings need to be replicated in larger, controlled clinical trials.


Cocaine Gabapentin Baclofen Amantadine Selegiline 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



This research was supported by grants from National Institute on Drug Abuse (P-50 DA 12762 and K05-DA 0454). The authors declare no conflict of interest directly relevant to the contents of this review.


  1. 1.
    United States Substance Abuse and Mental Health Services Administration, Office of Applied Studies. National household survey on drug abuse. Rockville (MD): US Dept of Health and Human Services Public Health Service, 2001Google Scholar
  2. 2.
    Godfrey C, Stewart D, Gossop M. Economic analysis of costs and consequences of the treatment of drug misuse: 2-year outcome data from the National Treatment Outcome Research Study (NTORS). Addiction 2004 Jun; 99(6): 697–707PubMedGoogle Scholar
  3. 3.
    Flynn PM, Kristiansen PL, Porto JV, et al. Costs and benefits of treatment for cocaine addiction in DATOS. Drug Alcohol Depend 1999 Dec; 57(2): 167–74PubMedGoogle Scholar
  4. 4.
    Soares BG, Lima MS, Reisser AA, et al. Dopamine agonists for cocaine dependence. Cochrane Database Syst Rev 2003; (2): CD003352Google Scholar
  5. 5.
    Lima MS, Reisser AA, Soares BG, et al. Antidepressants for cocaine dependence. Cochrane Database Syst Rev 2003; (2): CD002023Google Scholar
  6. 6.
    de Lima MS, de Oliveira Soares BG, Reisser AA, et al. Pharmacological treatment of cocaine dependence: a systematic review. Addiction 2002; 97(8): 931–49PubMedGoogle Scholar
  7. 7.
    Kosten TR, Sofuoglu M. Stimulants. In: The American Psychiatric Press textbook of substance abuse treatment. 3rd ed. Washington, DC: The American Psychiatric Press, 2004Google Scholar
  8. 8.
    Bardo MT. Neuropharmacological mechanisms of drug reward: beyond dopamine in the nucleus accumbens. Crit Rev Neurobiol 1998; 12(1-2): 37–67PubMedGoogle Scholar
  9. 9.
    Koob GF. Neural mechanisms of drug reinforcement. Ann N Y Acad Sci 1992 Jun 28; 654: 171–91PubMedGoogle Scholar
  10. 10.
    Tzschentke TM, Schmidt WJ. Functional relationship among medial prefrontal cortex, nucleus accumbens, and ventral tegmental area in locomotion and reward. Crit Rev Neurobiol 2000; 14(2): 131–42PubMedGoogle Scholar
  11. 11.
    Tzschentke TM. Pharmacology and behavioral pharmacology of the mesocortical dopamine system. Prog Neurobiol 2001 Feb; 63(3): 241–320PubMedGoogle Scholar
  12. 12.
    Markou A, Koob GF. Postcocaine anhedonia: an animal model of cocaine withdrawal. Neuropsychopharmacology 1991 Jan; 4(1): 17–26PubMedGoogle Scholar
  13. 13.
    Koob GF, Caine SB, Parsons L, et al. Opponent process model and psychostimulant addiction. Pharmacol Biochem Behav 1997 Jul; 57(3): 513–21PubMedGoogle Scholar
  14. 14.
    Sofuoglu M, Dudish-Poulsen S, Brown SB, etal. Association of cocaine withdrawal symptoms with more severe dependence and enhanced subjective response to cocaine. Drug Alcohol Depend 2003 Apr 1; 69(3): 273–82PubMedGoogle Scholar
  15. 15.
    Sealfon SC, Olanow CW. Dopamine receptors: from structure to behavior. Trends Neurosci 2000 Oct; 23(10 Suppl.): S34–40PubMedGoogle Scholar
  16. 16.
    Sokoloff P, Schwartz JC. Novel dopamine receptors half a decade later. Trends Pharmacol Sci 1995 Aug; 16(8): 270–5PubMedGoogle Scholar
  17. 17.
    Missale C, Nash SR, Robinson SW, et al. Dopamine receptors: from structure to function. Physiol Rev 1998 Jan; 78(1): 189–225PubMedGoogle Scholar
  18. 18.
    Mitchell ES, Snyder-Keller A. Blockade of D1 dopaminergic transmission alleviates c-fos induction and cleaved caspase-3 expression in the brains of rat pups exposed to prenatal cocaine or perinatal asphyxia. Exp Neurol 2003 Jul; 182(1): 64–74PubMedGoogle Scholar
  19. 19.
    Sanchez CJ, Bailie TM, Wu WR, et al. Manipulation of dopamine d1-like receptor activation in the rat medial prefrontal cortex alters stress- and cocaine-induced reinstatement of conditioned place preference behavior. Neuroscience 2003; 119(2): 497–505PubMedGoogle Scholar
  20. 20.
    Khroyan TV, Platt DM, Rowlett JK, et al. Attenuation of relapse to cocaine seeking by dopamine D1 receptor agonists and antagonists in non-human primates. Psychopharmacology (Berl) 2003 Jul; 168(1-2): 124–31Google Scholar
  21. 21.
    Chausmer AL, Elmer GI, Rubinstein M, et al. Cocaine-induced locomotor activity and cocaine discrimination in dopamine D2 receptor mutant mice. Psychopharmacology (Berl) 2002 Aug; 163(1): 54–61Google Scholar
  22. 22.
    Platt DM, Rodefer JS, Rowlett JK, et al. Suppression of cocaine- and food-maintained behavior by the D2-like receptor partial agonist terguride in squirrel monkeys. Psychopharmacology (Berl) 2003 Mar; 166(3): 298–305Google Scholar
  23. 23.
    Caine SB, Negus SS, Mello NK, et al. Role of dopamine D2-like receptors in cocaine self-administration: studies with D2 receptor mutant mice and novel D2 receptor antagonists. J Neurosci 2002 Apr 1; 22(7): 2977–88PubMedGoogle Scholar
  24. 24.
    Costanza RM, Barber DJ, Terry P. Antagonism of the discriminative stimulus effects of cocaine at two training doses by dopamine D2-like receptor antagonists. Psychopharmacology (Berl) 2001 Nov; 158(2): 146–53Google Scholar
  25. 25.
    Conners CK. Forty years of methylphenidate treatment in attention-deficit/ hyperactivity disorder. J Atten Disord 2002; 6Suppl. 1: S17–30PubMedGoogle Scholar
  26. 26.
    Schenk JO. The functioning neuronal transporter for dopamine: kinetic mechanisms and effects of amphetamines, cocaine and methylphenidate. Prog Drug Res 2002; 59: 111–31PubMedGoogle Scholar
  27. 27.
    Volkow ND, Fowler JS, Wang GJ, et al. Role of dopamine in the therapeutic and reinforcing effects of methylphenidate in humans: results from imaging studies. Eur Neuropsycho-pharmacol 2002; 12(6): 557–66Google Scholar
  28. 28.
    Grabowski J, Roache JD, Schmitz JM, et al. Replacement medication for cocaine dependence: methylphenidate. J Clin Psychopharmacol 1997; 17(6): 485–8PubMedGoogle Scholar
  29. 29.
    Schubiner H, Saules KK, Arfken CL, et al. Double-blind placebo-controlled trial of methylphenidate in the treatment of adult ADHD patients with comorbid cocaine dependence. Exp Clin Psychopharmacol 2002; 10(3): 286–94PubMedGoogle Scholar
  30. 30.
    Halpern A, Mancini MC. Treatment of obesity: an update on anti-obesity medications. Obes Rev 2003 Feb; 4(1): 25–42PubMedGoogle Scholar
  31. 31.
    Preston KL, Sullivan JT, Berger P, et al. Effects of cocaine alone and in combination with mazindol in human cocaine abusers. J Pharmacol Exp Ther 1993; 267(1): 296–307PubMedGoogle Scholar
  32. 32.
    Stine SM, Krystal JH, Kosten TR, et al. Mazindol treatment for cocaine dependence. Drug Alcohol Depend 1995; 39(3): 245–52PubMedGoogle Scholar
  33. 33.
    Margolin A, Avants SK, Kosten TR. Mazindol for relapse prevention to cocaine abuse in methadone-maintained patients. Am J Drug Alcohol Abuse 1995; 21(4): 469–81PubMedGoogle Scholar
  34. 34.
    Blanchet PJ, Metman LV, Chase TN. Renaissance of amantadine in the treatment of Parkinson’s disease. Adv Neurol 2003; 91: 251–7PubMedGoogle Scholar
  35. 35.
    Crosby N, Deane KH, Clarke CE. Amantadine in Parkinson’s disease. Cochrane Database Syst Rev 2003; (1): CD003468Google Scholar
  36. 36.
    Heimans RL, Rand MJ, Fennessy MR. Effects of amantadine on uptake and release of dopamine by a particulate fraction of rat basal ganglia. J Pharm Pharmacol 1972 Nov; 24(11): 875–9PubMedGoogle Scholar
  37. 37.
    Stoof JC, Booij J, Drukarch B, et al. The anti-parkinsonian drug amantadine inhibits the N-methyl-D-aspartic acid-evoked release of acetylcholine from rat neostriatum in a non-competitive way. Eur J Pharmacol 1992 Mar 31; 213(3): 439–43PubMedGoogle Scholar
  38. 38.
    Nastuk WL, Su P, Doubilet P. Anticholinergic and membrane activities of amantadine in neuromuscular transmission. Nature 1976 Nov 4; 264(5581): 76–9PubMedGoogle Scholar
  39. 39.
    Collins ED, Vosburg SK, Hart CL, et al. Amantadine does not modulate reinforcing, subjective, or cardiovascular effects of cocaine in humans. Pharmacol Biochem Behav 2003 Dec; 76(3-4): 401–7PubMedGoogle Scholar
  40. 40.
    Alterman AI, Droba M, Antelo RE, et al. Amantadine may facilitate detoxification of cocaine addicts. Drug Alcohol Depend 1992; 31(1): 19–29PubMedGoogle Scholar
  41. 41.
    Kampman K, Volpicelli JR, Alterman A, et al. Amantadine in the early treatment of cocaine dependence: a double-blind, placebo-controlled trial. Drug Alcohol Depend 1996; 41(1): 25–33PubMedGoogle Scholar
  42. 42.
    Kampman KM, Volpicelli JR, Alterman AI, et al. Amantadine in the treatment of cocaine-dependent patients with severe withdrawal symptoms. Am J Psychiatry 2000; 157(12): 2052–4PubMedGoogle Scholar
  43. 43.
    Shoptaw S, Kintaudi PC, Charuvastra C, et al. A screening trial of amantadine as a medication for cocaine dependence. Drug Alcohol Depend 2002; 66(3): 217–24PubMedGoogle Scholar
  44. 44.
    Myllyla VV, Sotaniemi K, Maki-Ikola O, et al. Role of selegiline in combination therapy of Parkinson’s disease. Neurology 1996; 47(6 Suppl. 3): S200–209PubMedGoogle Scholar
  45. 45.
    Ebadi M, Sharma S, Shavali S, et al. Neuroprotective actions of selegiline. J Neurosci Res 2002; 67(3): 285–9PubMedGoogle Scholar
  46. 46.
    Haberny KA, Walsh SL, Ginn DH, et al. Absence of acute cocaine interactions with the MAO-B inhibitor selegiline. Drug Alcohol Depend 1995; 39(1): 55–62PubMedGoogle Scholar
  47. 47.
    Bartzokis G, Beckson M, Newton T, et al. Selegiline effects on cocaine-induced changes in medial temporal lobe metabolism and subjective ratings of euphoria. Neuropsychopharmacology 1999; 20(6): 582–90PubMedGoogle Scholar
  48. 48.
    Hughes JC, Cook CC. The efficacy of disulfiram: a review of outcome studies. Addiction 1997; 92(4): 381–95PubMedGoogle Scholar
  49. 49.
    Nagendra SN, Faiman MD, Davis K, et al. Carbamoylation of brain glutamate receptors by a disulfiram metabolite. J Biol Chem 1997; 272(39): 24247–51PubMedGoogle Scholar
  50. 50.
    McCance-Katz EF, Kosten TR, Jatlow P. Disulfiram effects on acute cocaine administration. Drug Alcohol Depend 1998; 52(1): 27–39PubMedGoogle Scholar
  51. 51.
    Carroll KM, Nich C, Ball SA, et al. Treatment of cocaine and alcohol dependence with psychotherapy and disulfiram. Addiction 1998; 93(5): 713–27PubMedGoogle Scholar
  52. 52.
    Petrakis IL, Carroll KM, Nich C, et al. Disulfiram treatment for cocaine dependence in methadone-maintained opioid addicts. Addiction 2000; 95(2): 219–28PubMedGoogle Scholar
  53. 53.
    George TP, Chawarski MC, Pakes J, et al. Disulfiram versus placebo for cocaine dependence in buprenorphine-maintained subjects: a preliminary trial. Biol Psychiatry 2000; 47(12): 1080–6PubMedGoogle Scholar
  54. 54.
    Carroll KM, Fenton LR, Ball SA, et al. Efficacy of disulfiram and cognitive-behavioral therapy in cocaine-dependent outpatients: a randomized placebo-controlled trial. Arch Gen Psychiatry 2004; 61(3): 264–72PubMedGoogle Scholar
  55. 55.
    Giardina WJ, Williams M. Adrogolide HCl (ABT-431; DAS-431), a prodrug of the dopamine D1 receptor agonist, A-86929: preclinical pharmacology and clinical data. CNS Drug Rev 2001; 7(3): 305–16PubMedGoogle Scholar
  56. 56.
    Haney M, Collins ED, Ward AS, et al. Effect of a selective dopamine D1 agonist (ABT-431) on smoked cocaine self-administration in humans. Psychopharmacology 1999; 143(1): 102–10PubMedGoogle Scholar
  57. 57.
    Romach MK, Glue P, Kampman K, et al. Attenuation of the euphoric effects of cocaine by the dopamine D1/D5 antagonist ecopipam (SCH 39166). Arch Gen Psychiatry 1999; 56(12): 1101–6PubMedGoogle Scholar
  58. 58.
    Nann-Vernotica E, Donny EC, Bigelow GE, et al. Repeated administration of the D1/5 antagonist ecopipam fails to attenuate the subjective effects of cocaine. Psychopharmacology 2001; 155(4): 338–47PubMedGoogle Scholar
  59. 59.
    Haney M, Ward AS, Foltin RW, et al. Effects of ecopipam, a selective dopamine D1 antagonist, on smoked cocaine self-administration by humans. Psychopharmacology 2001; 155(4): 330–7PubMedGoogle Scholar
  60. 60.
    Ho KY, Thorner MO. Therapeutic applications of bromocriptine in endocrine and neurological diseases. Drugs 1988 Jul; 36(1): 67–82PubMedGoogle Scholar
  61. 61.
    Jackson DM, Jenkins OF, Ross SB. The motor effects of bromocriptine: a review. Psychopharmacology (Berl) 1988; 95(4): 433–46Google Scholar
  62. 62.
    Kumor K, Sherer M, Jaffe J. Effects of bromocriptine pretreatment on subjective and physiological responses to i.v. cocaine. Pharmacol Biochem Behav 1989; 33(4): 829–37Google Scholar
  63. 63.
    Preston KL, Sullivan JT, Strain EC, et al. Effects of cocaine alone and in combination with bromocriptine in human cocaine abusers. J Pharmacol Exp Ther 1992; 262(1): 279–91PubMedGoogle Scholar
  64. 64.
    Moscovitz H, Brookoff D, Nelson L. A randomized trial of bromocriptine for cocaine users presenting to the emergency department. J Gen Intern Med 1993; 8(1): 1–4PubMedGoogle Scholar
  65. 65.
    Handelsman L, Rosenblum A, Palij M, et al. Bromocriptine for cocaine dependence: a controlled clinical trial. Am J Addict 1997; 6(1): 54–64PubMedGoogle Scholar
  66. 66.
    Montoya ID, Preston KL, Rothman R, et al. Open-label pilot study of bupropion plus bromocriptine for treatment of cocaine dependence. Am J Drug Alcohol Abuse 2002; 28(1): 189–96PubMedGoogle Scholar
  67. 67.
    Dewey SL, Morgan AE, Ashby CR, et al. A novel strategy for the treatment of cocaine addiction. Synapse 1998 Oct; 30(2): 119–29PubMedGoogle Scholar
  68. 68.
    Cousins MS, Roberts DC, de Wit H. GABA (B) receptor agonists for the treatment of drug addiction: a review of recent findings. Drug Alcohol Depend 2002; 65(3): 209–20PubMedGoogle Scholar
  69. 69.
    Brebner K, Childress AR, Roberts DC. A potential role for GABA (B) agonists in the treatment of psychostimulant addiction. Alcohol Alcohol 2002; 37(5): 478–84PubMedGoogle Scholar
  70. 70.
    McFarland K, Kalivas PW. The circuitry mediating cocaine-induced reinstatement of drug-seeking behavior. J Neurosci 2001; 21(21): 8655–63PubMedGoogle Scholar
  71. 71.
    Kushner SA, Unterwald EM. Chronic cocaine administration decreases the functional coupling of GABA (B) receptors in the rat ventral tegmental area as measured by baclofen-stimulated 35S-GTPgammaS binding. Life Sci 2001; 69(9): 1093–102PubMedGoogle Scholar
  72. 72.
    Suzuki T, Abe S, Yamaguchi M, et al. Effects of cocaine administration on receptor binding and subunits mRNA of GABA (A)-benzodiazepine receptor complexes. Synapse 2000; 38(2): 198–215PubMedGoogle Scholar
  73. 73.
    Yamaguchi M, Suzuki T, Abe S, et al. Repeated cocaine administration increases GABA (B (1)) subunit mRNA in rat brain. Synapse 2002; 43(3): 175–80PubMedGoogle Scholar
  74. 74.
    Li J, Olinger AB, Dassow MS, et al. Up-regulation of GABA (B) receptor mRNA and protein in the hippocampus of cocaine- and lidocaine-kindled rats. Neuroscience 2003; 118(2): 451–62PubMedGoogle Scholar
  75. 75.
    Dewey SL, Chaurasia CS, Chen CE, et al. GABAergic attenuation of cocaine-induced dopamine release and locomotor activity. Synapse 1997; 25(4): 393–8PubMedGoogle Scholar
  76. 76.
    Gerasimov MR, Schiffer WK, Gardner EL, et al. GABAergic blockade of cocaine-associated cue-induced increases in nucleus accumbens dopamine. Eur J Pharmacol 2001; 414(2-3): 205–9PubMedGoogle Scholar
  77. 77.
    Watanabe M, Maemura K, Kanbara K, et al. GABA and GABA receptors in the central nervous system and other organs. Int Rev Cytol 2002; 213: 1–47PubMedGoogle Scholar
  78. 78.
    Loscher W. Basic pharmacology of valproate: a review after 35 years of clinical use for the treatment of epilepsy. CNS Drugs 2002; 16(10): 669–94PubMedGoogle Scholar
  79. 79.
    Soudijn W, van Wijngaarden I. The GABA transporter and its inhibitors. Curr Med Chem 2000 Oct; 7(10): 1063–79PubMedGoogle Scholar
  80. 80.
    Borden LA. GABA transporter heterogeneity: pharmacology and cellular localization. Neurochem Int 1996 Oct; 29(4): 335–56PubMedGoogle Scholar
  81. 81.
    Mehta AK, Ticku MK. An update on GABAA receptors. Brain Res Brain Res Rev 1999 Apr; 29(2-3): 196–217PubMedGoogle Scholar
  82. 82.
    Luscher B, Fritschy JM. Subcellular localization and regulation of GABAA receptors and associated proteins. Int Rev Neurobiol 2001; 48: 31–64PubMedGoogle Scholar
  83. 83.
    Hevers W, Luddens H. The diversity of GABAA receptors. Pharmacological and electrophysiological properties of GABAA channel subtypes. Mol Neurobiol 1998 Aug; 18(1): 35–86Google Scholar
  84. 84.
    Mohler H, Fritschy JM, Rudolph U. A new benzodiazepine pharmacology. J Pharmacol Exp Ther 2002 Jan; 300(1): 2–8PubMedGoogle Scholar
  85. 85.
    Sundstrom Poromaa I, Smith S, Gulinello M. GABA receptors, progesterone and premenstrual dysphoric disorder. Arch Women Ment Health 2003 Feb; 6(1): 23–41Google Scholar
  86. 86.
    Blein S, Hawrot E, Barlow P. The metabotropic GABA receptor: molecular insights and their functional consequences. Cell Mol Life Sci 2000 Apr; 57(4): 635–50PubMedGoogle Scholar
  87. 87.
    Misgeld U, Bijak M, Jarolimek W. A physiological role for GABAB receptors and the effects of baclofen in the mammalian central nervous system. Prog Neurobiol 1995 Jul; 46(4): 423–62PubMedGoogle Scholar
  88. 88.
    Myrick H, Henderson S, Brady KT, et al. Divalproex loading in the treatment of cocaine dependence. J Psychoactive Drugs 2001; 33(3): 283–7PubMedGoogle Scholar
  89. 89.
    Halikas JA, Center BA, Pearson VL, et al. A pilot, open clinical study of depakote in the treatment of cocaine abuse. Hum Psychopharmacol 2001; 16(3): 257–64PubMedGoogle Scholar
  90. 90.
    Gibbs JW, Sombati S, DeLorenzo RJ, et al. Cellular actions of topiramate: blockade of kainate-evoked inward currents in cultured hippocampal neurons. Epilepsia 2000; 41Suppl. 1: S10–16PubMedGoogle Scholar
  91. 91.
    Herrero AI, Del Olmo N, Gonzalez-Escalada JR, et al. Two new actions of topiramate: inhibition of depolarizing GABA (A)-mediated responses and activation of a potassium conductance. Neuropharmacology 2002; 42(2): 210–20PubMedGoogle Scholar
  92. 92.
    Shank RP, Gardocki JF, Streeter AJ, et al. An overview of the preclinical aspects of topiramate: pharmacology, pharmaco-kinetics, and mechanism of action. Epilepsia 2000; 41Suppl. 1: S3–9PubMedGoogle Scholar
  93. 93.
    White HS, Brown SD, Woodhead JH, et al. Topiramate modulates GABA-evoked currents in murine cortical neurons by a nonbenzodiazepine mechanism. Epilepsia 2000; 41Suppl. 1: S17–20PubMedGoogle Scholar
  94. 94.
    Gordey M, DeLorey TM, Olsen RW. Differential sensitivity of recombinant GABA (A) receptors expressed in Xenopus oocytes to modulation by topiramate. Epilepsia 2000; 41Suppl. 1: S25–29PubMedGoogle Scholar
  95. 95.
    Kampman KM, Pettinati H, Lynch KG, et al. A pilot trial of topiramate for the treatment of cocaine dependence. Drug Alcohol Depend 2004 Sep 6; 75(3): 233–40PubMedGoogle Scholar
  96. 96.
    Schachter SC. Pharmacology and clinical experience with tiagabine. Expert Opin Pharmacother 2001; 2(1): 179–87PubMedGoogle Scholar
  97. 97.
    Gonzalez G, Sevarino K, Sofuoglu M, et al. Tiagabine increases cocaine-free urines in cocaine-dependent methadone-treated patients: results of a randomized pilot study. Addiction 2003 Nov; 98(11): 1625–32PubMedGoogle Scholar
  98. 98.
    González G, Sofuoglu M, Gonsai K, et al. Efficacy of tiagabine or gabapentin in reducing cocaine use in methadone-stabilized cocaine abusers. [abstract]. College on Problems of Drug Dependence. 65th Annual Scientific Meeting; 2003 Jun 14–19; Bal Harbour (FL)Google Scholar
  99. 99.
    Shoptaw S, Yang X, Rotheram-Fuller EJ, et al. Randomized placebo-controlled trial of baclofen for cocaine dependence: preliminary effects for individuals with chronic patterns of cocaine use. J Clin Psychiatry 2003; 64(12): 1440–8PubMedGoogle Scholar
  100. 100.
    Leach JP, Sills GJ, Butler E, et al. Neurochemical actions of gabapentin in mouse brain. Epilepsy Res 1997; 27(3): 175–80PubMedGoogle Scholar
  101. 101.
    Taylor CP, Gee NS, Su TZ, et al. A summary of mechanistic hypotheses of gabapentin pharmacology. Epilepsy Res 1998; 29(3): 233–49PubMedGoogle Scholar
  102. 102.
    Hart CL, Ward AS, Collins ED, et al. Gabapentin maintenance decreases smoked cocaine-related subjective effects, but not self-administration by humans. Drug Alcohol Depend 2004 Mar 8; 73(3): 279–87PubMedGoogle Scholar
  103. 103.
    Bisaga A, Aharonovich E, Nunes E. Gabapentin treatment of cocaine dependence [abstract]. College on Problems of Drug Dependence. 65th Annual Scientific Meeting; 2003 Jun 14–19; Bal Harbour (FL)Google Scholar
  104. 104.
    Baulieu EE. Neurosteroids: a novel function of the brain. Psychoneuroendocrinology 1998; 23(8): 963–87PubMedGoogle Scholar
  105. 105.
    Smith SS. Progesterone administration attenuates excitatory amino acid responses of cerebellar Purkinje cells. Neuroscience 1991; 42(2): 309–20PubMedGoogle Scholar
  106. 106.
    Matsumoto RR, McCracken KA, Pouw B, et al. Involvement of sigma receptors in the behavioral effects of cocaine: evidence from novel ligands and antisense oligodeoxynucleotides. Neuropharmacology 2002; 42(8): 1043–55PubMedGoogle Scholar
  107. 107.
    Sofuoglu M, Babb DA, Hatsukami DK. Effects of progesterone treatment on smoked cocaine response in women. Pharmacol Biochem Behav 2002; 72(1-2): 431–5PubMedGoogle Scholar
  108. 108.
    Sofuoglu M, Mitchell E, Kosten TR. Effects of progesterone treatment on cocaine responses in male and female cocaine users. Pharmacol Biochem Behav 2004 Aug; 78(4): 699–705PubMedGoogle Scholar
  109. 109.
    Schindler CW, Tella SR, Erzouki HK, et al. Pharmacological mechanisms in cocaine’s cardiovascular effects. Drug Alcohol Depend 1995; 37(3): 183–91PubMedGoogle Scholar
  110. 110.
    Robbins TW, Granon S, Muir JL, etal. Neural systems underlying arousal and attention: implications for drug abuse. Ann N Y Acad Sci 1998; 846: 222–37PubMedGoogle Scholar
  111. 111.
    Harris GC, Aston-Jones G. Beta-adrenergic antagonists attenuate withdrawal anxiety in cocaine- and morphine-dependent rats. Psychopharmacology 1993; 113(1): 131–6PubMedGoogle Scholar
  112. 112.
    Harris GC, Hedaya MA, Pan WJ, et al. Beta-adrenergic antagonism alters the behavioral and neurochemical responses to cocaine. Neuropsychopharmacology 1996; 14(3): 195–204PubMedGoogle Scholar
  113. 113.
    Berthold CW, Gonzales RA, Moerschbaecher JM. Prazosin attenuates the effects of cocaine on motor activity but not on schedule-controlled behavior in the rat. Pharmacol Biochem Behav 1992; 43(1): 111–5PubMedGoogle Scholar
  114. 114.
    Johanson CE, Barrett JE. The discriminative stimulus effects of cocaine in pigeons. J Pharmacol Exp Ther 1993; 267(1): 1–8PubMedGoogle Scholar
  115. 115.
    Spealman RD. Noradrenergic involvement in the discriminative stimulus effects of cocaine in squirrel monkeys. J Pharmacol Exp Ther 1995; 275(1): 53–62PubMedGoogle Scholar
  116. 116.
    Sofuoglu M, Brown S, Babb DA, et al. Effects of labetalol treatment on the physiological and subjective response to smoked cocaine. Pharmacol Biochem Behav 2000 Feb; 65(2): 255–9PubMedGoogle Scholar
  117. 117.
    Sofuoglu M, Brown S, Babb DA, et al. Carvedilol affects the physiological and behavioral response to smoked cocaine in humans. Drug Alcohol Depend 2000 Jul 1; 60(1): 69–76PubMedGoogle Scholar
  118. 118.
    Tham TC, Guy S, McDermott BJ, et al. The dose dependency of the alpha- and beta-adrenoceptor antagonist activity of carvedilol in man. Br J Clin Pharmacol 1995; 40(1): 19–23PubMedGoogle Scholar
  119. 119.
    Kampman KM, Volpicelli JR, Mulvaney F, et al. Effectiveness of propranolol for cocaine dependence treatment may depend on cocaine withdrawal symptom severity. Drug Alcohol Depend 2001 Jun 1; 63(1): 69–78PubMedGoogle Scholar
  120. 120.
    Frishman WH. Beta-adrenergic blockers. Med Clin North Am 1988; 72(1): 37–81PubMedGoogle Scholar
  121. 121.
    Kosten TR. Pharmacotherapy of cerebral ischemia in cocaine dependence. Drug Alcohol Depend 1998; 49(2): 133–44PubMedGoogle Scholar
  122. 122.
    Bolla KI, Funderburk FR, Cadet JL. Differential effects of cocaine and cocaine alcohol on neurocognitive performance. Neurology 2000; 54(12): 2285–92PubMedGoogle Scholar
  123. 123.
    Di Sclafani V, Tolou-Shams M, Price LJ, et al. Neuropsychological performance of individuals dependent on crack-cocaine, or crack-cocaine and alcohol, at 6 weeks and 6 months of abstinence. Drug Alcohol Depend 2002; 66(2): 161–71PubMedGoogle Scholar
  124. 124.
    Gottschalk C, Beauvais J, Hart R, et al. Cognitive function and cerebral perfusion during cocaine abstinence. Am J Psychiatry 2001; 158(4): 540–5PubMedGoogle Scholar
  125. 125.
    Kosten TR, Gottschalk PC, Tucker K, et al. Aspirin or amiloride for cerebral perfusion defects in cocaine dependence. Drug Alcohol Depend 2003; 71(2): 187–94PubMedGoogle Scholar
  126. 126.
    Gottschalk PC, Kosten TR. Isradipine enhancement of cerebral blood flow in abstinent cocaine abusers with and without chronic perfusion deficits. Am J Addict 2002; 11(3): 200–8PubMedGoogle Scholar
  127. 127.
    Johnson B, Barron B, Fang B, et al. Isradipine prevents global and regional cocaine-induced changes in brain blood flow: a preliminary study. Psychopharmacology 1998; 136(4): 335–41PubMedGoogle Scholar
  128. 128.
    Sofuoglu M, Singha A, Kosten TR, et al. Effects of naltrexone and isradipine, alone or in combination, on cocaine responses in humans. Pharmacol Biochem Behav 2003 Jul; 75(4): 801–8PubMedGoogle Scholar
  129. 129.
    Kosten TR, Rosen M, Bond J, et al. Human therapeutic cocaine vaccine: safety and immunogenicity. Vaccine 2002; 20(7-8): 1196–204PubMedGoogle Scholar
  130. 130.
    Fox BS, Kantak KM, Edwards MA, et al. Efficacy of a therapeutic cocaine vaccine in rodent models. Nat Med 1996; 2(10): 1129–32PubMedGoogle Scholar
  131. 131.
    Fox BS. Development of a therapeutic vaccine for the treatment of cocaine addiction. Drug Alcohol Depend 1997; 48: 153–8PubMedGoogle Scholar
  132. 132.
    Bonese KF, Wainer BH, Fitch FW, et al. Changes in heroin self-administration by a rhesus monkey after morphine immunization. Nature 1974; 252: 708–10PubMedGoogle Scholar
  133. 133.
    Killian A, Bonese K, Rothberg RM, et al. Effects of passive immunization against morphine on heroin self-administration. Pharmacol Biochem Behav 1978; 9: 347–52PubMedGoogle Scholar
  134. 134.
    Kantak KM, Collins SL, Lipman EG, et al. Evaluation of anticocaine antibodies and a cocaine vaccine in a rat self-administration model. Psychopharmacology 2000; 148(3): 251–62PubMedGoogle Scholar
  135. 135.
    Kosten TR, Rosen M, Bond J, et al. Human therapeutic cocaine vaccine: safety and immunogenicity. Vaccine 2002; 20: 1196–204PubMedGoogle Scholar
  136. 136.
    Kosten TR. Cocaine vaccines [abstract]. College on problems of drug dependence. 65th Annual Scientific Meeting; 2003 Jun 14–19; Bal Harbour (FL)Google Scholar

Copyright information

© Adis Data Information BV 2005

Authors and Affiliations

  1. 1.School of Medicine, Department of Psychiatry and VA Connecticut Healthcare SystemYale UniversityWest HavenUSA

Personalised recommendations